EU/3/19/2135

Table of contents

About

On 26 February 2019, orphan designation (EU/3/19/2135) was granted by the European Commission to Enzyvant Therapeutics Ireland Limited, Ireland, for allogeneic cultured postnatal thymus-derived tissue (also known as RVT-802) for the treatment of DiGeorge syndrome.

Key facts

Active substance
Allogeneic cultured postnatal thymus-derived tissue
Disease / condition
Treatment of DiGeorge syndrome
Date of first decision
26/02/2019
Outcome
Positive
EU designation number
EU/3/19/2135

Sponsor's contact details

Enzyvant Therapeutics Ireland Limited
88 Harcourt Street
Dublin 2 D02 DK18
Ireland
Tel. +353 87 7206017
E-mail: info@enzyvant.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating